Active, not recruitingPhase 4NCT05309785
Safety and Efficacy of Canagliflozin in Advanced CKD
Studying Complication in hemodialysis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Principal Investigator
- Thomas Mavrakanas, MDResearch Institute of the McGill University Health Center
- Intervention
- Invokana 300 mg and 100 mg tablet(drug)
- Enrollment
- 35 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (1)
- McGill University Health Center, Montreal, Quebec, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05309785 on ClinicalTrials.govOther trials for Complication in hemodialysis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07438925Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure VariationCentral Hospital, Nancy, France
- RECRUITINGNANCT06341452Comparison of Individualized Sodium Management Versus Standard Treatment in HemodialysisFresenius Medical Care Deutschland GmbH
- RECRUITINGNANCT07512895The Effect of Progressive Muscle Relaxation Exercises on Depression and Fatigue in Patients Receiving Hemodialysis Treatment: A Randomized Controlled TrialIstanbul Aydın University
- RECRUITINGNANCT07269379Intradialytic Exercise With Blood Flow Restriction in Hemodialysis PatientsUniversity of Avignon
- ACTIVE NOT RECRUITINGNCT07412834Safely Disconnect From the Dialysis Machine in an Emergency SituationIstanbul University
- RECRUITINGPHASE1NCT07217886A Study of S-892216-PO in Participants With Renal Impairment and Matched ControlsShionogi
- RECRUITINGNANCT06978127Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis PatientsUniversity of Pittsburgh
- ACTIVE NOT RECRUITINGPHASE3NCT06901505To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisAkebia Therapeutics